| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 years from now) | |
| US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7741358 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(3 years from now) | |
|
US8022228 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(3 years from now) | |
Saphris is owned by Allergan.
Saphris contains Asenapine Maleate.
Saphris has a total of 4 drug patents out of which 0 drug patents have expired.
Saphris was authorised for market use on 13 August, 2009.
Saphris is available in tablet;sublingual dosage forms.
Saphris can be used as use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; treatment of bipolar disorder and schizophrenia; use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: as adjunctive treatment to lithium or valproate in adults; use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes in pediatric patients age 10-17; use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes (ages 10 to adult); method of treating manic or mixed episodes associated with bipolar disorder in pediatric patients; use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults.
The generics of Saphris are possible to be released after 06 October, 2026.
Drugs and Companies using ASENAPINE MALEATE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; Treatment of bipolar disorder and schizophrenia; Use of the atypical antipsychotic asenapine for treatment of mani...
Dosage: TABLET;SUBLINGUAL
SAPHRIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic